miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models

miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models

Show other versions (1)

Palbociclib is in early-stage clinical testing in advanced hepatocellular carcinoma (HCC). Here, we investigated whether the anti-tumor activity of palbociclib, which prevents the CDK4/6-mediated phosphorylation of RB1 but simultaneously activates AKT signaling, could be improved by its combination...

Full description

Bibliographic Details
Main Authors: Elisa Callegari, Paola Guerriero, Cristian Bassi, Lucilla D’Abundo, Antonio Frassoldati, Edi Simoni, Laura Astolfi, Enrico Maria Silini, Silvia Sabbioni, Massimo Negrini
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
Oligonucleotides: Therapies and Applications
HCC
palbociclib
MK-2206
mir-199a-3p
anti-tumor therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253122001846

Internet

http://www.sciencedirect.com/science/article/pii/S2162253122001846

Similar Items